Preventing Irreversible Disability in NMOSD through Timely Diagnosis and Treatment: Payer and Provider Perspectives

Neuromyelitis optica spectrum disorder (NMOSD) is a rare neurodegenerative inflammatory disease of the optic nerve and spinal cord. NMOSD has significant clinical and economic implications; plus, diagnosis and treatment selection can be challenging. Fortunately, recently-approved targeted therapies can reduce the frequency of relapses and improve patient outcomes. Join us for part one of this two-part webinar series as leading NMOSD and managed care experts discuss: 

• Timely diagnosis and accurate assessment of disease severity 
• The latest clinical data for novel targeted therapies and appropriate selection 
• Real-world patient perspectives on living with NMOSD 
• Expert strategies to integrate patient characteristics and emerging evidence into clinical and managed care decision-making

Learning Objectives: 

• Assess the clinical and economic burden of neuromyelitis optica spectrum disorder (NMOSD), including the impact of delayed diagnosis and treatment on patient outcomes 
• Evaluate advances in diagnostic techniques for accurate diagnosis and assessment of NMOSD severity 
• Differentiate therapies for NMOSD based on mechanisms of action, mode of administration, and clinical data on efficacy and safety 
• Align decision-making with current evidence and patient factors to ensure appropriate patient selection and prompt access to NMOSD therapies 

Agenda:  

1. Real-world Patient Perspectives on the Challenges in Diagnosis and Management of NMOSD 
2. Differentiation of NMOSD From MS: Disease Recognition, Diagnosis and Assessment 
3. Differentiating Therapies for NMOSD: The Latest Mechanism of Action, Mode of Administration, and Efficacy and Safety Data 
4. Expert Strategies to Interpret and Apply Current Evidence, Patient-Specific Factors, and Economic Considerations Into Clinical Practice and Managed Care Decisions 

Sponsored by: 

For individuals from the media/press who are interested in attending, please email media@amcp.org.  

Register Today